Novel chimeric TLR2/NOD2 agonist CL429 exhibited significant radioprotective effects in mice. Issue 8 (19th February 2021)

• Record Type: Journal Article
• Authors: Cheng, Ying; Du, Jicong; Liu, Ruling; Dong, Suhe; Cai, Jianming; Gao, Fu; Liu, Cong
• Is Part Of: Journal of cellular and molecular medicine. Volume 25:Issue 8(2021)
• Page Start: 3785
• Page End: 3792
• Publication Date: 2021-02-19
• Subjects: Cl429 -- NOD2 -- radiation -- radioprotection -- TLR2; Cytology; Medicine; Molecular Biology; Cytologie -- Périodiques; Médecine -- Périodiques; Biologie moléculaire -- Périodiques; Cytology -- Periodicals; Medicine -- Periodicals; Molecular biology -- Periodicals; 611.01805
• DOI: 10.1111/jcmm.16252
• Languages: English
• ISSNs: 1582-1838

Abstract

Abstract: Severe ionizing radiation causes the acute lethal damage of haematopoietic system and gastrointestinal tract. Here, we found CL429, the novel chimeric TLR2/NOD2 agonist, exhibited significant radioprotective effects in mice. CL429 increased mice survival, protected mice against the lethal damage of haematopoietic system and gastrointestinal tract. CL429 was more effective than equivalent amounts of monospecific (TLR2 or NOD2) and combination (TLR2 + NOD2) of molecules in preventing radiation‐induced death. The radioprotection of CL429 was mainly mediated by activating TLR2 and partially activating NOD2. CL429‐induced radioprotection was largely dependent on the activation of TLR2‐MyD88‐NF‐κB signalling pathway. In conclusion, the data suggested that the co‐activation of TLR2 and NOD2 could induce significant synergistic radioprotective effects and CL429 might be a potential high‐efficiency selective agent.